Chimerix to Announce Third Quarter 2016 Financial Results on November 7, 2016
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 97022450. A live audio webcast of the call will also be available on the Investors' section of the Company's website, www.chimerix.com. An archived webcast will be available on the
About
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel
antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates.
CONTACT: Investor Relations: ir@chimerix.com or Will O'Connor Stern Investor Relations will@sternir.com 212-362-1200 Media: Becky VonsiatskySource:W2O Group bvonsiatsky@w2ogroup.com 413-478-2003
News Provided by Acquire Media